EASL 2018

infohep news

• NAFLD

  Mixed results for experimental therapies for NASH

  Liz Highleyman / 22 June 2018

  The recent International Liver Congress in Paris featured several presentations on investigational therapies for fatty liver disease. Drugs with a range of different mechanisms – including the thyroid hormone receptor agonist MGL-3196, ...

• Hepatitis C elimination

  Georgia: 98% cured of hepatitis C

  Keith Alcorn / 23 May 2018

  Georgia is making strong progress towards eliminating hepatitis C but will need triple the number of people starting treatment if it is to reach its national elimination target of a ...

• Hepatocellular carcinoma (HCC)

  T cell immunotherapy shows promise for treating liver cancer

  Liz Highleyman / 22 May 2018

  Personalised immunotherapy reduces the risk of liver cancer recurrence and may lead to tumour regression, according to a pair of studies presented at the 2018 International Liver Congress last month in Paris. In ...

• Life after the cure

  Do fatigue and quality of life improve after hepatitis C is cured?

  Keith Alcorn / 15 May 2018

  Patient-reported outcomes such as fatigue, vitality and mental health improve substantially in the two years following hepatitis C cure for people with cirrhosis, but people with cirrhosis are less likely ...

• Treatment outcomes

  Does portal hypertension always improve after hepatitis C cure?

  Keith Alcorn / 10 May 2018

  Although portal hypertension improves in the majority of people with hepatitis C and cirrhosis after hepatitis C is cured, not all people experience improvement, and oesophageal varices may continue to ...

• Treatment for people who use drugs

  Combining hepatitis C therapy and buprenorphine leads to good outcomes for people who inject drugs

  Liz Highleyman / 08 May 2018

  Offering hepatitis C treatment and opioid substitution therapy with buprenorphine at the same location can help increase adherence and reduce harms associated with injection drug use, according to findings from the ANCHOR study ...

• Antiviral therapy

  Switching to TAF improves safety in people with hepatitis B with kidney and bone risk factors

  Liz Highleyman / 04 May 2018

  People with risk factors for tenofovir toxicity who switched from tenofovir disoproxil fumarate (TDF; Viread) to the new tenofovir alafenamide (TAF; Vemlidy) maintained hepatitis B virus (HBV) suppression and showed evidence of improved kidney and ...

• Treatment outcomes

  Fewer non-liver cancers in people treated with DAAs compared to the interferon era

  Keith Alcorn / 02 May 2018

  The risk of non-liver cancer is lower in people treated with direct-acting antivirals (DAAs) than in those treated with interferon and is probably an effect of the improved cure rate ...

• Hepatitis D

  Myrcludex B plus tenofovir suppresses hepatitis delta

  Liz Highleyman / 30 April 2018

  An experimental drug that blocks the entry of hepatitis B virus (HBV) and hepatitis delta virus (HDV) into liver cells suppressed HBV and HDV levels and led to improvement in ...

• Hepatocellular carcinoma (HCC)

  Local therapy with sorafenib does not improve liver cancer survival

  Liz Highleyman / 23 April 2018

  Combining sorafenib (Nexavar) with internal radiation therapy or transarterial chemoembolization did not improve overall survival for people with liver cancer, but it did appear to help certain groups of patients, according to research presented ...